Det estimeres, at vaccinens effekt over for vaccineserotype AOM, det primære slutresultat af undersøgelsen, var 57% (95% CI:
The estimate for vaccine efficacy against vaccine-serotype AOM, the primary endpoint of the trial, was 57% (95% CI: